Study: NCT03471871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 25 mg
Description: HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 25 mg
Description: HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 25 mg
Description: HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.